A study to find a suitable dose of ASP5834 in adults with solid tumors
5834-CL-1001
Phase 1 other active
Quick answer
A study to find a suitable dose of ASP5834 in adults with solid tumors for Locally advanced (unresectable) or metastatic solid tumor malignancies who harbor a KRAS mutation (G12V, G12D, G12C, G12A, G12R or G13D mutation) or KRAS amplification is a Phase 1 program (other) at Astellas Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Astellas Pharma GmbH
- Indication
- Locally advanced (unresectable) or metastatic solid tumor malignancies who harbor a KRAS mutation (G12V, G12D, G12C, G12A, G12R or G13D mutation) or KRAS amplification
- Phase
- Phase 1
- Modality
- other
- Status
- active